The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin LymphomaПодробнее

Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphomaПодробнее

Brentuximab Vedotin Plus AVD: Limiting Toxicity in Limited-Stage Hodgkin LymphomaПодробнее

Can A+AVD replace PET-directed strategies for the frontline treatment of Hodgkin lymphoma?Подробнее

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphomaПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin LymphomaПодробнее

Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphomaПодробнее

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVDПодробнее

Research Builds On Positive ECHELON-1 Study in Hodgkin LymphomaПодробнее

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 studyПодробнее

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphomaПодробнее

Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma PatientsПодробнее

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphomaПодробнее

Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin LymphomaПодробнее

ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVDПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphomaПодробнее